Cancer Genetics, Inc. (CGIX) EPS Estimated At $-0.11

March 13, 2018 - By Max Morgan

 Cancer Genetics, Inc. (CGIX) EPS Estimated At $ 0.11
Investors sentiment decreased to 0.57 in Q3 2017. Its down 0.60, from 1.17 in 2017Q2. It turned negative, as 5 investors sold Cancer Genetics, Inc. shares while 9 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.58 million shares or 6.28% less from 2.76 million shares in 2017Q2 were reported.
Thompson Davis stated it has 0.22% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Pnc Fincl Services Grp Incorporated holds 0% or 6,000 shares. 15,301 were reported by Hrt Financial Ltd Liability Corp. Perkins Management owns 806,700 shares. Diker Management Ltd Liability reported 0.07% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Northern Trust Corporation holds 34,771 shares or 0% of its portfolio. Wells Fargo & Mn stated it has 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Next Group Inc Inc accumulated 2,500 shares or 0% of the stock. The United Kingdom-based Barclays Plc has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Renaissance Technologies Ltd Liability Co reported 569,400 shares stake. Royal Fincl Bank Of Canada has 809 shares. Granahan Inv Management Inc Ma holds 237,431 shares. State Bank Of Montreal Can owns 24,212 shares. 17,998 are owned by Morgan Stanley. Commercial Bank Of America De accumulated 625 shares.

Since December 15, 2017, it had 1 buying transaction, and 0 insider sales for $24,339 activity.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.11 EPS on March, 22.They anticipate $0.04 EPS change or 26.67 % from last quarter’s $-0.15 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -31.25 % EPS growth. It closed at $2 lastly. It is down 81.82% since March 13, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Cancer Genetics had 11 analyst reports since March 11, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, January 16 with “Buy”. The stock has “Neutral” rating by Janney Capital on Friday, March 11. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Buy” rating by H.C. Wainwright on Tuesday, August 15. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, February 6 with “Buy” rating. The rating was initiated by Maxim Group with “Buy” on Thursday, December 7. As per Wednesday, November 29, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the shares of CGIX in report on Thursday, September 21 with “Buy” rating. The rating was initiated by Rodman & Renshaw on Monday, September 26 with “Buy”. Aegis Capital maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, March 15 with “Buy” rating.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $48.51 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Another recent and important Cancer Genetics, Inc. (NASDAQ:CGIX) news was published by which published an article titled: “You Can Now Order an At-Home Genetic Test for Breast Cancer. But Should You?” on March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.